Prostate Cancer Treatment with Actinium-225 PSMA (program ID: 447926)

University Hospital Würzburg

location_on Würzburg, Germany
9.2/10 from 38 Votes
Specialized hospital
Andreas Buck

Head Physician
Prof. Dr. med.

Andreas Buck

Specialized in: nuclear medicine

Department of Nuclear Medicine

Program includes:

  • Initial presentation in the clinic
  • clinical history taking
  • general physical examination
  • laboratory tests:
    • complete blood count
    • biochemical analysis of blood
    • urinalysis
    • TSH-basal, fT3, fT4
    • PSA blood level
    • tests for urogenital infections
    • indicators of inflammation
    • indicators of blood coagulation
  • ultrasound scan of the urogenital system
  • renal scintigraphy
  • PSMA treatment with Actinium-225
  • full body scintigraphy after 24 hours
  • full body scintigraphy after 48 hours
  • symptomatic treatment
  • cost of essential medicines
  • nursing services
  • elaboration of further recommendations
  • stay in the hospital with full board 
  • accommodation in 2-bedded room 

How program is carried out

During the first visit, the doctor will carry out a general physical examination and go through the results of previous laboratory and instrumental tests. After that, you will undergo the necessary additional tests such as the assessment of liver and kidney function, scintigraphy of the skeleton and salivary glands, PSMA PET / CT. This will allow the doctor to assess how effective PSMA therapy with Actinium-225 will be and how well you will tolerate it. Also, the doctor will calculate your individual dosage of the radionuclide.

PSMA therapy with Actinium-225 is carried out via intravenous administration of a solution with the radioactive isotope Actinium-225. The solution is injected through a catheter. This is a short procedure, as the infusion usually takes no more than 20 minutes.

During the procedure, you will need to apply cooling bags to the salivary glands, as Actinium-225 partially accumulates in the salivary glands, affecting their function and causing dry mouth. You will also receive intravenous saline solutions to protect your kidneys.

After the infusion of Actinium-225, you will stay in a specially equipped (radiation-shielded) ward for 48 hours. The drug is quickly excreted by the kidneys, and after 48 hours you will no longer be dangerous to others. During these 48 hours, you can read, use a mobile phone, tablet or computer – all these devices will not be a source of radiation in the future.

Follow-up examinations include whole-body scintigraphy or computed tomography in 24 hours and 48 hours after the procedure. Based on the results of the examination, the doctor will determine whether one procedure is enough for you, or whether you will need to visit the hospital again. As a rule, 1-2 procedures are required for achieving a stable positive result. Procedures are carried out with an interval of 8 weeks.

Required documents

  • Medical records
  • PSA blood test
  • MRI/CT scan (not older than 3 months)
  • Bone scintigraphy (if available)
  • Biopsy results (if available)
Type of program :
Expected duration of the program:

You may also book


About the department

The Department of Nuclear Medicine at the University Hospital Würzburg offers all modern diagnostic and therapeutic procedures using radioactive substances. In addition to the classical methods of nuclear diagnostics, for example, thyroid scintigraphy, special attention is paid to the functional and molecular imaging using the state-of-art PET-CT and SPECT-CT techniques. The department is headed by Prof. Dr. med. Andreas Buck.

A special feature of the department is also the Section of Radiochemistry, which produces its own radiopharmaceutical medicines for the targeted therapy of oncopathology (including prostate cancer, neuroendocrine tumors or lymphomas), diseases of the cardiovascular system, and neurological disorders.

The department is engaged in active research activities, which allowed to introduce into clinical practice many innovations, for example, PSMA therapy with radiotherapy pharmaceutical medication Lutetium-177 for prostate cancer treatment, DOTATOC therapy with radiopharmaceutical medication Lutetium-177 for the treatment of neuroendocrine tumors. In addition, as a part of clinical trials, the department offers the treatment of adrenal carcinoma with Iodometidate-131 or the treatment of multiple myeloma and other malignant neoplasms with the help of the CXCR4 Chemokine Receptor-Ligand associated with Lutetium-177.

The diagnostic and therapeutic service range of the department covers the following options:

  • Pain therapy
    • Pain therapy in bone metastases
    • Radiosynoviorthese (RSO) in inflammatory joint diseases
  • Radioiodine therapy in cancer and other thyroid diseases
  • Cancer therapy
    • Peptide receptor radionuclide therapy using Lu-177/Y-90-Dotatate
    • Lu-177 PSMA therapy
    • Lu-177/Y-90-CXCR4 therapy
  • Thyroid diagnostics (within the specialized outpatient clinic)
    • Ultrasound examinations
    • Scintigraphy
    • SPECT-CT
    • PET CT
    • Laboratory tests
  • Combined PET-CT technique
  • Scintigraphy
  • SPECT-CT diagnostics
  • Treatment within the clinical trials
  • Other medical services

Photo of the doctor: (c) Universitätsklinikum Würzburg 

About hospital

Accommodation in hospital

There are 26 metastatic prostate cancer treatment hospitals on Booking Health website

Show all clinics


Need Help?

Thank you!

We received your treatment application in the best Europe clinics. Our manager will contact you within the next 24 hours.